Navigation Links
CEL-SCI Launches Study to Determine Long Lasting Beneficial Effects of its Rheumatoid Arthritis Vaccine
Date:1/7/2009

is Multikine(R) which is being readied for a global Phase III trial. The Company has operations in Vienna, Virginia, and Baltimore, Maryland. CEL-SCI's other products, which are currently in pre-clinical stage, have shown protection against a number of diseases in animal tests and are being tested against diseases associated with bio-defense and avian flu.

When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its report on Form 10- K for the year ended September 30, 2007. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE CEL-SCI Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. CEL-SCI Presents Favorable Data for Leaps Vaccine Technology at Prestigious Immunology Conference
2. CEL-SCI Corporation Reports Second Quarter 2008 Financial Results
3. CEL-SCI CORPORATION Announces Results of 2008 Annual Meeting of Shareholders and Provides Update on Ground-breaking Activities Regarding Construction of Manufacturing Facility for Pivotal Phase III Cancer Trial
4. CEL-SCI Corporation Releases Letter to Shareholders
5. CEL-SCI Corporation Announces Adoption of Shareholder Rights Plan
6. Comprehensive Review of Cancer Immnunotherapies Published By CEL-SCI
7. Surf Sweets Launches Natural, Organic Candy Line at More Than 250 Toys"R"Us Stores Across the Country
8. ChildRC.com Launches The Child Resource Center
9. First Service Design Firm Launches in United States
10. The Doctors Company Launches Southeast Legal Summit to Provide Industry's Best Claims Defense for Physicians
11. Florida Breast Augmentation Surgeon Launches State-of-the-Art Website Reflecting his Unique Approach
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... School of Medicine in St. Louis helps explain why ... are more harmful than similar tumors in females. For ... diagnosed twice as often in males, who suffer greater ... long. , The researchers found that retinoblastoma protein (RB), ... less active in male brain cells than in female ...
(Date:8/1/2014)... The U.S. Food and Drug Administration announced on Friday ... fight type 2 diabetes. Jardiance (empagliflozin) "can ... to control blood sugar levels in the overall management ... of Drug Evaluation II in the FDA,s Center for ... The FDA also recommended that Jardiance be used ...
(Date:8/1/2014)... The evolving healthcare landscape presents ... At ThoughtSpot 2014, AmerisourceBergen and Good Neighbor Pharmacy’s ... resources to enhance patient care and profitability. At ... issues to give independent pharmacists the tools they ... ThoughtSpot show attendance experienced a nearly 70% increase ...
(Date:8/1/2014)... 01, 2014 Growing prevalence of ... healthcare reforms are boosting healthcare market growth, although ... discounts and increasing generic consumption is a major ... million in 2013, having grown at a Compound ... The implementation of the Health Transformation Program (Saglikta ...
(Date:8/1/2014)... 2014 (HealthDay News) -- Patients with the progressive, deadly ... have a new weapon to battle the disease, the ... The agency approved a new treatment, an inhaled spray ... killer of Americans. COPD, which is often linked to ... and emphysema. Patients with COPD may experience ...
Breaking Medicine News(10 mins):Health News:Study reveals one reason brain tumors are more common in men 2Health News:FDA Approves New Type 2 Diabetes Drug 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 3Health News:ThoughtSpot 2014 Inspires as General Session Concludes 4Health News:ThoughtSpot 2014 Inspires as General Session Concludes 5Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 2Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 3Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 4Health News:FDA Approves New Treatment for People With COPD 2
... ROCK, Ark., Oct. 20 Heifer International, http://www.heifer.org, ... gift alternative for the green-minded client, the hard-to-shop-for,person ... tighter gift budgets.,Heifer focuses on doing one thing ... billion people living on less than $2 a ...
... Ride Home" , ... Alameda, California (PRWEB) October 20, 2008 -- Alameda-based ... of holidays for the Safe and Sober Free Cab Ride Home program. ... in Alameda and Luxor Cab in San Francisco to provide free transportation ...
... for treatment for GERD and Erosive ... Esophagitis, ... that Takeda Global Research and,Development Center, Inc., a wholly owned United States ... agency will not be able to complete its review of the TAK-390MR ...
... Young Throats, FARMINGDALE, N.Y., Oct. 18 ... Group, Ltd. (IBG), a manufacturer,of innovative sports and ... Throat Cooler(R). This non-medicated ready-to-freeze,liquid product is a ... a 100%,drug free product to help hydrate and ...
... approximately one,in eight couples of childbearing age are infertile, ... specialist for help trying to conceive,(source: CDC)., Conceive ... who,wants to keep herself healthy so she can achieve ... are thinking about family building,and the new special issue, ...
... CALGARY, Oct. 17 /PRNewswire-FirstCall/ - The Westaim ... between its wholly owned,subsidiary iFire Technology Ltd. ... will sell its equipment, patents and intellectual ... The sale is subject to,several conditions, including ...
Cached Medicine News:Health News:Heifer International: The Greener Good for Holiday Giving 2Health News:Free Cab Rides Home for Halloween in Alameda, Oakland, Berkeley and San Francisco, California 2Health News:Free Cab Rides Home for Halloween in Alameda, Oakland, Berkeley and San Francisco, California 3Health News:FDA Adds Three Months to Review of Takeda's New Drug Application for TAK-390MR 2Health News:Integrated Beverage Group Launches Children's Throat Cooler(R) 2Health News:Integrated Beverage Group Launches Children's Throat Cooler(R) 3Health News:Conceive Magazine Introduces a Special Issue: 'The Birds, The Bees, and Modern Medicine' 2Health News:Westaim announces sale of iFire Technology Ltd. assets 2
(Date:8/1/2014)... , Aug. 1, 2014 MGC ... technologies company, announced today that it has completed ... manufacturer of cardiorespiratory diagnostic products based in Sorinnes, ... has served the European cardiorespiratory diagnostics market since ... revenues of approximately €4.7 million ($6.3 million) and ...
(Date:8/1/2014)... 1, 2014 Dyadic International, Inc. ("Dyadic") (OTCQX: ... technologies are used to develop, manufacture and sell enzymes ... and industrial enzyme industries, announced today that it will ... June 30, 2014 after market close on Thursday, August ... day at 5:00 p.m. Eastern Time to discuss those ...
(Date:7/31/2014)... , July 31, 2014  Sorrento Therapeutics, Inc. (NASDAQ: ... Mr. Amar Singh , Chief Business Officer and Executive ... natural causes on July 30. "Sorrento is deeply ... and colleague. Our immediate thoughts go to Amar,s family and ... Chief Executive Officer. Mr. Singh joined Sorrento ...
Breaking Medicine Technology:MGC Diagnostics Corporation Completes Acquisition of MediSoft SA 2MGC Diagnostics Corporation Completes Acquisition of MediSoft SA 3MGC Diagnostics Corporation Completes Acquisition of MediSoft SA 4Dyadic International To Announce Second Quarter 2014 Financial Results And Host Conference Call On Thursday, August 14, 2014 2Dyadic International To Announce Second Quarter 2014 Financial Results And Host Conference Call On Thursday, August 14, 2014 3Sorrento Announces the Unexpected Death of its Chief Business Officer 2
... Research Group (MRG), the global authority on medical ... over $30 million in 2010. Revenues, however, remained ... prices and greater market penetration of refurbished scopes. ... manufacturers are being forced to promote creative options ...
... MORRISTOWN, N.J., Oct. 27 Watson Pharmaceuticals, Inc. (NYSE: ... Watson Laboratories, Inc., filed a new drug application under ... Act (FFDCA) with the U.S. Food and Drug Administration ... 20 and 40 mg tablets.  Watson,s rosuvastatin zinc tablets ...
Cached Medicine Technology:Despite Rising Procedure Volumes, the $30 Million European Arthroscope Market Experienced Nominal Growth in 2010 2Despite Rising Procedure Volumes, the $30 Million European Arthroscope Market Experienced Nominal Growth in 2010 3Watson Confirms Crestor® Patent Challenge 2
... Tip Laryngoscopes are the most ... The articulating tip aids during ... improved view of epiglottis. Available ... styles. We guarantee your complete ...
CCR Medical conventional laryngoscopes....
CCR Medical conventional laryngoscopes....
CCR Medical conventional laryngoscopes....
Medicine Products: